Bladder cancer is a urological tumor with high rates of recurrence despite recent advances in novel therapies.Many proteins involved in the molecular mechanisms are currently an enigma,especially the transmembrane 9 s...Bladder cancer is a urological tumor with high rates of recurrence despite recent advances in novel therapies.Many proteins involved in the molecular mechanisms are currently an enigma,especially the transmembrane 9 superfamily member 1 which has an unclear function.Wei et al published the function and mechanism of this protein,and showed that it could participate in the proliferation,migration and invasion of tumor cells in bladder cancer,therefore treatments directed against this protein may be beneficial in avoiding this condition.展开更多
MicroRNAs （miRNAs or miRs） are a class of short, non-coding RNAs that participate in various oncological processes. This study aims to explore the roles of microRNA-34a （miR-34a） in invasive urothelial bladder car...MicroRNAs （miRNAs or miRs） are a class of short, non-coding RNAs that participate in various oncological processes. This study aims to explore the roles of microRNA-34a （miR-34a） in invasive urothelial bladder carcinoma. miR-34a was transfected into bladder cancer cell lines 253J and J82. The miR-34a expression levels in tissues and cells were detected by using qRT-PCR. The Notch1 expression was detected by qRT-PCR and Western blotting. Cell migratory and invasive abilities were measured by Transwell chamber assay. Bioinformatics and luciferase assay were performed to predict and analyze the binding sites between miRNA-34a and Notch1. It was found that there was aberrant expression of miR-34a in bladder cancer tissues. Moreover, we revealed that ectopic expression of miR-34a suppressed cell migration and invasion, while forced expression of Notch1 increased cell migratory and invasive abilities. Finally, we observed that miR-34a transfection significantly down-regulated luciferase activity and reduced the mRNA and protein levels of Notch1. Our study concluded that microRNA-34a antagonizes Notch1 and inhibits cell migration and invasion of bladder cancer cells, which indicates the tumor-suppressive function of microRNA-34a in bladder cancer.展开更多
The purpose of this study was to determine the relationship between hypermethylation of DACT1 gene pro-moter and lower mRNA expression in bladder urothelial carcinoma tissue.The methylation status of 29 urothelial car...The purpose of this study was to determine the relationship between hypermethylation of DACT1 gene pro-moter and lower mRNA expression in bladder urothelial carcinoma tissue.The methylation status of 29 urothelial carcinoma samples and 29 normal tissue samples were examined by methylation-specific polymerase chain reac-tion（MSP）.The DACT1 mRNA transcript levels and DACT1 protein levels in all samples were then evaluated to define the relationship between the methylation status of the DACT1 promoter and its expression at the transcrip-tional and translational levels.Decreased expression of DACT1 was detected in 89.66% of urothelial carcinomas（26/29;P 〈 0.005）.Promoter hypermethylation was found in 58.62%（17/29） urothelial carcinomas and 25%（7/29） normal tissues,respectively（P 〈 0.05）.DACT1 expression was lower in tissues where the DACT1 gene promoter was hypermethylated than in unmethylated tissues（0.25±0.17 vs 0.69±0.30,P 〈 0.05）.DACT1 gene hyper-methylation was closely related to tumor size,grade and stage（P 〈 0.05）.Our results indicate that silencing and downregulation of DACT1 mRNA may be implicated in carcinogenesis and the progression of bladder urothelial carcinoma,and may be a potential prognostic factor.展开更多
Background and Objective: The outcome of locally advanced and metastatic urothelial carcinoma LA/mUC has improved over the past years with a plethora of new treatments and the approval of immune checkpoint inhibitors ...Background and Objective: The outcome of locally advanced and metastatic urothelial carcinoma LA/mUC has improved over the past years with a plethora of new treatments and the approval of immune checkpoint inhibitors (ICIs), antibody-drug conjugates, and targeted agents, to identify locally advanced metastatic urothelial carcinoma’s current management practices in Lebanon and the implication of the ongoing economic crisis on the medical practice. Methods: An online questionnaire was used to survey ten Lebanese oncologists from six different hospitals, between July 5 and July 11, 2022, requesting information pertaining to their current clinical practice in the pharmacological treatment of locally advanced metastatic urothelial carcinoma. Key Findings: Cisplatin-based chemotherapy was the most frequently reported initial treatment of locally advanced metastatic urothelial carcinoma. Participants reported using immune checkpoint inhibitors in platinum-ineligible patients and those with PDL1 positive tumors. Also, they would not consider the concomitant use of immunotherapy and chemotherapy in the first-line setting. Participants believed that avelumab maintenance is effective in the absence of progression after first-line platinum-based chemotherapy;they would consider initiating it 2 - 10 weeks after completion of chemotherapy. Conclusions and Clinical Implications: After comparing with current international guidelines, this study shows that Lebanese oncologists follow international guidelines and have deep knowledge of recent clinical trials for the management of locally advanced metastatic urothelial carcinoma, regardless of economic crisis challenges.展开更多
Objective:The aim of our study was to clarify the clinicopathological factors affecting the outcome of T1G3 urothelial carcinoma of the bladder.Methods:We retrospectively reviewed 62 cases of T1G3 bladder cancer treat...Objective:The aim of our study was to clarify the clinicopathological factors affecting the outcome of T1G3 urothelial carcinoma of the bladder.Methods:We retrospectively reviewed 62 cases of T1G3 bladder cancer treated with transuretheral resection of bladder toumor (TURBT) followed by intravesical instillation between 1997 and 2009.Cumulative survival was analyzed by Kaplan-Meier method.Cox regression was used for univariate and multivariate analysis.Log-rank method was used for the significance test.The statistical difference was accepted when the P value was lower than 0.05.Results:Median follow-up period was 40 months (6-140 months).Forty-one cases of intravesical recurrence (66%) were observed during follow-up.Two-and 5-year recurrence-free survival rates were 43.4% and 35.1%.Fourteen cases of progression (23%) were observed during the follow-up period.Two-and 5-year progression-free survival rates were 86.4% and 83.5%,respectively.Significant factors for tumor recurrence and progression were analyzed by Cox regression.Tumor multiplicity (RR=2.250),size (RR=1.039) and history of recurrence (RR=2.162) were significantly correlated with recurrence and tumor multiplicity (RR=3.695) was significantly correlated with progression on multivariate analysis.Conclusion:Tumor multiplicity,size,history of recurrence were correlated with recurrence and tumor multiplicity was significantly correlated with progression.Tumor multiplicity,size and history of recurrence should be taken into account when we make therapy strategies for T1G3 urothelial carcinoma of the bladder.展开更多
Bladder cancer is one of the most common cancers in the world, and about 80%-90% of bladder cancers are urothelial cancer. Neoadjuvant platinum-based combination chemotherapy is considered to be the standard treatment...Bladder cancer is one of the most common cancers in the world, and about 80%-90% of bladder cancers are urothelial cancer. Neoadjuvant platinum-based combination chemotherapy is considered to be the standard treatment for bladder cancer. However, the use of this treatment has clinical disadvantages such as small overall benefit, toxic effects on the target population, and inability to select the most beneficial patients. This phenomenon has been improved by the presence of immunological checkpoint inhibitors, of which PD-1/PDL-1 inhibitors are one of them. The use of PD-1/ PD-L1 in urinary cancer is a new treatment and offers new hope for the treatment of platinum-refractory metastatic urothelial bladder cancer. Related drugs have now been approved for use in patients with refractory or unqualified platinum-based chemotherapy drugs. Clinical trials are currently underway to determine how best to use these drugs, and whether they should be used alone or in combination with other treatments. This article will review the research progress of PD-1/PDL-1 inhibitors in bladder tumors.展开更多
Background:Ferroptosis is an iron dependent form of cell death,which plays an important role in the pathogenesis of a variety of urinary malignancies.The down-regulation of DECR1 gene causes the accumulation of polyun...Background:Ferroptosis is an iron dependent form of cell death,which plays an important role in the pathogenesis of a variety of urinary malignancies.The down-regulation of DECR1 gene causes the accumulation of polyunsaturated fatty acids(PUFAs),increases the susceptibility to lipid peroxidation,and finally leads to cell death.Methods:We first searched the data to find reductase 1(DECR1)expression in bladder uroepithelial carcinoma and healthy surrounding tissues in the Cancer Genome Atlas(TCGA),and we then confirmed DECR1 expression with additional independent cohorts in the Gene Expression Omnibus(GEO)database and the Human Protein Atlas(HPA).In order to determine the link between DECR1 expression and clinical traits and overall survival(OS),as well as to create nomograms,multivariate analysis and Kaplan Meier survival curves were utilized.Through the use of an online string website,the network of proteins that interact with DECR1 was created.Through an online string website,the protein network interacting with DECR1 was built.Finally,we looked at the association between aggressive immune cells and the marker genes that belong to them and DECR1 expression.Results:When compared to normal tissues,bladder tumor tissues had higher DECR1 expression(P=0.002).Low DECR1 expression was linked with tumor grade and stage in tumor cells.BLCA patients with low DECR1 expression had a lower overall survival than BLCA patients with high DECR1 expression,according to a survival study(P=0.008).The protein network’s HSD17B4 and DECR1 connections are crucial.The expression of regulatory T cells,regulatory B cells,and their markers were decreased when DECR1 was missing in bladder cancer.Conclusion:Decreased DECR1 expression was associated with BLCA progression,poor prognosis and impaired infiltration of some immune cells.展开更多
目的:探讨血小板与白细胞比值(platelet and white blood cells ratio, PWR)、血小板与淋巴细胞比值(platelet and lymphocyte ratio, PLR)、中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio, NLR)以及尿白细胞计数(urinary l...目的:探讨血小板与白细胞比值(platelet and white blood cells ratio, PWR)、血小板与淋巴细胞比值(platelet and lymphocyte ratio, PLR)、中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio, NLR)以及尿白细胞计数(urinary leucocyte count, ULEU)与接受PD-1抑制剂治疗晚期尿路上皮癌(urothelial carcinoma, UC)患者预后的关系。方法:收集78例接受PD-1抑制剂治疗晚期UC患者的临床资料,利用Kaplan-Meier法计算生存率和Log-rank检验比较不同组间的生存差异,同时采用COX回归分析预后影响因素。结果:低PLR组与高PLR组的1年生存率分别为71.98%和47.63%,差异有统计学意义(P<0.05);低NLR组与高NLR组的1年生存率分别为71.36%和48.15%,差异有统计学意义(P<0.05);PWR高低两组和ULEU状态预测UC患者生存率无显著性差异(P>0.05)。单因素回归分析结果显示,N分期、M分期、TNM分期、远处转移个数、PLR、NLR是影响晚期UC患者生存情况的危险因素(P<0.05)。多因素回归分析显示,PLR是影响接受PD-1抑制剂治疗的UC患者预后的独立因素。结论:PLR、NLR为影响接受PD-1抑制剂治疗晚期UC患者预后的独立因素,PLR高值组和NLR高值组患者的预后较PLR低值组和NLR低值组的患者差。展开更多
文摘Bladder cancer is a urological tumor with high rates of recurrence despite recent advances in novel therapies.Many proteins involved in the molecular mechanisms are currently an enigma,especially the transmembrane 9 superfamily member 1 which has an unclear function.Wei et al published the function and mechanism of this protein,and showed that it could participate in the proliferation,migration and invasion of tumor cells in bladder cancer,therefore treatments directed against this protein may be beneficial in avoiding this condition.
基金supported by a grant from the National Natural Science Foundation of China(No.30972982)
文摘MicroRNAs （miRNAs or miRs） are a class of short, non-coding RNAs that participate in various oncological processes. This study aims to explore the roles of microRNA-34a （miR-34a） in invasive urothelial bladder carcinoma. miR-34a was transfected into bladder cancer cell lines 253J and J82. The miR-34a expression levels in tissues and cells were detected by using qRT-PCR. The Notch1 expression was detected by qRT-PCR and Western blotting. Cell migratory and invasive abilities were measured by Transwell chamber assay. Bioinformatics and luciferase assay were performed to predict and analyze the binding sites between miRNA-34a and Notch1. It was found that there was aberrant expression of miR-34a in bladder cancer tissues. Moreover, we revealed that ectopic expression of miR-34a suppressed cell migration and invasion, while forced expression of Notch1 increased cell migratory and invasive abilities. Finally, we observed that miR-34a transfection significantly down-regulated luciferase activity and reduced the mRNA and protein levels of Notch1. Our study concluded that microRNA-34a antagonizes Notch1 and inhibits cell migration and invasion of bladder cancer cells, which indicates the tumor-suppressive function of microRNA-34a in bladder cancer.
文摘The purpose of this study was to determine the relationship between hypermethylation of DACT1 gene pro-moter and lower mRNA expression in bladder urothelial carcinoma tissue.The methylation status of 29 urothelial carcinoma samples and 29 normal tissue samples were examined by methylation-specific polymerase chain reac-tion（MSP）.The DACT1 mRNA transcript levels and DACT1 protein levels in all samples were then evaluated to define the relationship between the methylation status of the DACT1 promoter and its expression at the transcrip-tional and translational levels.Decreased expression of DACT1 was detected in 89.66% of urothelial carcinomas（26/29;P 〈 0.005）.Promoter hypermethylation was found in 58.62%（17/29） urothelial carcinomas and 25%（7/29） normal tissues,respectively（P 〈 0.05）.DACT1 expression was lower in tissues where the DACT1 gene promoter was hypermethylated than in unmethylated tissues（0.25±0.17 vs 0.69±0.30,P 〈 0.05）.DACT1 gene hyper-methylation was closely related to tumor size,grade and stage（P 〈 0.05）.Our results indicate that silencing and downregulation of DACT1 mRNA may be implicated in carcinogenesis and the progression of bladder urothelial carcinoma,and may be a potential prognostic factor.
文摘Background and Objective: The outcome of locally advanced and metastatic urothelial carcinoma LA/mUC has improved over the past years with a plethora of new treatments and the approval of immune checkpoint inhibitors (ICIs), antibody-drug conjugates, and targeted agents, to identify locally advanced metastatic urothelial carcinoma’s current management practices in Lebanon and the implication of the ongoing economic crisis on the medical practice. Methods: An online questionnaire was used to survey ten Lebanese oncologists from six different hospitals, between July 5 and July 11, 2022, requesting information pertaining to their current clinical practice in the pharmacological treatment of locally advanced metastatic urothelial carcinoma. Key Findings: Cisplatin-based chemotherapy was the most frequently reported initial treatment of locally advanced metastatic urothelial carcinoma. Participants reported using immune checkpoint inhibitors in platinum-ineligible patients and those with PDL1 positive tumors. Also, they would not consider the concomitant use of immunotherapy and chemotherapy in the first-line setting. Participants believed that avelumab maintenance is effective in the absence of progression after first-line platinum-based chemotherapy;they would consider initiating it 2 - 10 weeks after completion of chemotherapy. Conclusions and Clinical Implications: After comparing with current international guidelines, this study shows that Lebanese oncologists follow international guidelines and have deep knowledge of recent clinical trials for the management of locally advanced metastatic urothelial carcinoma, regardless of economic crisis challenges.
文摘Objective:The aim of our study was to clarify the clinicopathological factors affecting the outcome of T1G3 urothelial carcinoma of the bladder.Methods:We retrospectively reviewed 62 cases of T1G3 bladder cancer treated with transuretheral resection of bladder toumor (TURBT) followed by intravesical instillation between 1997 and 2009.Cumulative survival was analyzed by Kaplan-Meier method.Cox regression was used for univariate and multivariate analysis.Log-rank method was used for the significance test.The statistical difference was accepted when the P value was lower than 0.05.Results:Median follow-up period was 40 months (6-140 months).Forty-one cases of intravesical recurrence (66%) were observed during follow-up.Two-and 5-year recurrence-free survival rates were 43.4% and 35.1%.Fourteen cases of progression (23%) were observed during the follow-up period.Two-and 5-year progression-free survival rates were 86.4% and 83.5%,respectively.Significant factors for tumor recurrence and progression were analyzed by Cox regression.Tumor multiplicity (RR=2.250),size (RR=1.039) and history of recurrence (RR=2.162) were significantly correlated with recurrence and tumor multiplicity (RR=3.695) was significantly correlated with progression on multivariate analysis.Conclusion:Tumor multiplicity,size,history of recurrence were correlated with recurrence and tumor multiplicity was significantly correlated with progression.Tumor multiplicity,size and history of recurrence should be taken into account when we make therapy strategies for T1G3 urothelial carcinoma of the bladder.
基金The National Natural Science Foundation of China.Project No:81672519.
文摘Bladder cancer is one of the most common cancers in the world, and about 80%-90% of bladder cancers are urothelial cancer. Neoadjuvant platinum-based combination chemotherapy is considered to be the standard treatment for bladder cancer. However, the use of this treatment has clinical disadvantages such as small overall benefit, toxic effects on the target population, and inability to select the most beneficial patients. This phenomenon has been improved by the presence of immunological checkpoint inhibitors, of which PD-1/PDL-1 inhibitors are one of them. The use of PD-1/ PD-L1 in urinary cancer is a new treatment and offers new hope for the treatment of platinum-refractory metastatic urothelial bladder cancer. Related drugs have now been approved for use in patients with refractory or unqualified platinum-based chemotherapy drugs. Clinical trials are currently underway to determine how best to use these drugs, and whether they should be used alone or in combination with other treatments. This article will review the research progress of PD-1/PDL-1 inhibitors in bladder tumors.
文摘Background:Ferroptosis is an iron dependent form of cell death,which plays an important role in the pathogenesis of a variety of urinary malignancies.The down-regulation of DECR1 gene causes the accumulation of polyunsaturated fatty acids(PUFAs),increases the susceptibility to lipid peroxidation,and finally leads to cell death.Methods:We first searched the data to find reductase 1(DECR1)expression in bladder uroepithelial carcinoma and healthy surrounding tissues in the Cancer Genome Atlas(TCGA),and we then confirmed DECR1 expression with additional independent cohorts in the Gene Expression Omnibus(GEO)database and the Human Protein Atlas(HPA).In order to determine the link between DECR1 expression and clinical traits and overall survival(OS),as well as to create nomograms,multivariate analysis and Kaplan Meier survival curves were utilized.Through the use of an online string website,the network of proteins that interact with DECR1 was created.Through an online string website,the protein network interacting with DECR1 was built.Finally,we looked at the association between aggressive immune cells and the marker genes that belong to them and DECR1 expression.Results:When compared to normal tissues,bladder tumor tissues had higher DECR1 expression(P=0.002).Low DECR1 expression was linked with tumor grade and stage in tumor cells.BLCA patients with low DECR1 expression had a lower overall survival than BLCA patients with high DECR1 expression,according to a survival study(P=0.008).The protein network’s HSD17B4 and DECR1 connections are crucial.The expression of regulatory T cells,regulatory B cells,and their markers were decreased when DECR1 was missing in bladder cancer.Conclusion:Decreased DECR1 expression was associated with BLCA progression,poor prognosis and impaired infiltration of some immune cells.
文摘目的:探讨血小板与白细胞比值(platelet and white blood cells ratio, PWR)、血小板与淋巴细胞比值(platelet and lymphocyte ratio, PLR)、中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio, NLR)以及尿白细胞计数(urinary leucocyte count, ULEU)与接受PD-1抑制剂治疗晚期尿路上皮癌(urothelial carcinoma, UC)患者预后的关系。方法:收集78例接受PD-1抑制剂治疗晚期UC患者的临床资料,利用Kaplan-Meier法计算生存率和Log-rank检验比较不同组间的生存差异,同时采用COX回归分析预后影响因素。结果:低PLR组与高PLR组的1年生存率分别为71.98%和47.63%,差异有统计学意义(P<0.05);低NLR组与高NLR组的1年生存率分别为71.36%和48.15%,差异有统计学意义(P<0.05);PWR高低两组和ULEU状态预测UC患者生存率无显著性差异(P>0.05)。单因素回归分析结果显示,N分期、M分期、TNM分期、远处转移个数、PLR、NLR是影响晚期UC患者生存情况的危险因素(P<0.05)。多因素回归分析显示,PLR是影响接受PD-1抑制剂治疗的UC患者预后的独立因素。结论:PLR、NLR为影响接受PD-1抑制剂治疗晚期UC患者预后的独立因素,PLR高值组和NLR高值组患者的预后较PLR低值组和NLR低值组的患者差。
